Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 23 analysts with 12-month price forecasts for Regeneron Pharmaceuticals stock have an average target of 907.39, with a low estimate of 547 and a high estimate of 1,200. The average target predicts an increase of 53.79% from the current stock price of 590.00.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$547	$907.39	$940	$1,200
Change	-7.29%	+53.79%	+59.32%	+103.39%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25	May '25
Strong Buy	7	7	7	7	6	6
Buy	12	12	13	12	12	12
Hold	4	5	5	5	4	4
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	24	25	26	25	23	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Maintains $940 → $810	Strong Buy	Maintains	$940 → $810	+37.29%	May 1, 2025
Srikripa Devarakonda Truist Securities	Truist Securities	Strong Buy Maintains $975 → $940	Strong Buy	Maintains	$975 → $940	+59.32%	Apr 30, 2025
Salveen Richter Goldman Sachs	Goldman Sachs	Strong Buy Maintains $917 → $804	Strong Buy	Maintains	$917 → $804	+36.27%	Apr 30, 2025
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $1,051 → $943	Buy	Maintains	$1,051 → $943	+59.83%	Apr 30, 2025
Mohit Bansal Wells Fargo	Wells Fargo	Buy Maintains $750 → $700	Buy	Maintains	$750 → $700	+18.64%	Apr 30, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

14.54B

Increased by 2.38%

from 14.20B

Revenue Next Year

15.65B

Increased by 7.65%

from 14.54B

EPS This Year

42.06

Increased by 9.69%

from 38.34

EPS Next Year

46.57

Increased by 10.73%

from 42.06

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	8.50B	16.07B	12.17B	13.12B	14.20B	14.54B	15.65B	17.01B
Revenue Growth	29.58%	89.14%	-24.26%	7.76%	8.27%	2.38%	7.65%	8.67%
EPS	30.52	71.97	38.22	34.77	38.34	42.06	46.57	55.11
EPS Growth	65.33%	135.81%	-46.90%	-9.03%	10.27%	9.69%	10.73%	18.35%
Forward PE	-	-	-	-	-	14.03	12.67	10.71
No. Analysts	-	-	-	-	-	30	28	22

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	16.3B	18.7B	19.2B
Avg	14.5B	15.7B	17.0B
Low	12.8B	13.5B	14.5B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	14.6%	28.4%	22.5%
Avg	2.4%	7.7%	8.7%
Low	-9.6%	-7.0%	-7.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	51.21	58.18	67.01
Avg	42.06	46.57	55.11
Low	32.92	35.46	37.92

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	33.6%	38.3%	43.9%
Avg	9.7%	10.7%	18.4%
Low	-14.1%	-15.7%	-18.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.